Ashokprabhu Namrita D, Fox Jessie, Henry Timothy D, Schmidt Christian W, Tierney Darlene, Gallatin Julie, Alvarez Yulith Roca, Thompson Lauren, Hamstra Michelle, Shah Sachin A, Quesada Odayme
Women's Heart Center, The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio; The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio.
Flow Therapy, Fort Worth, Texas; Thomas J Long School of Pharmacy, University of the Pacific, Stockton, California.
Am J Cardiol. 2024 Jan 15;211:89-93. doi: 10.1016/j.amjcard.2023.10.061. Epub 2023 Oct 27.
Angina and nonobstructive coronary artery disease (ANOCA) is associated with poor outcomes and limited treatment options. Enhanced external counterpulsation (EECP) is a noninvasive treatment that involves applying external inflatable cuffs to the lower extremities to increase blood flow during diastole, followed by deflation during systole. Although EECP is approved for treatment in patients with refractory angina due to obstructive coronary artery disease, its effectiveness in treating patients with ANOCA with refractory angina is limited to small studies. We assessed the efficacy of EECP treatment in patients with ANOCA (defined as ≤50% stenosis in any major epicardial vessels) with refractory anginaby measuring changes in Canadian Cardiovascular Society (CCS) angina class, 6-minute walk test, Duke Activity Status Index (DASI), Seattle Angina Questionnaire 7 (SAQ7), and weekly anginal episodes pre-EECP and post-EECP treatment. A total of 101 patients with ANOCA with CCS class III/IV angina completed a full course of EECP treatment at 2 large EECP centers. In 101 patients with ANOCA the mean age (SD) of 60.6 (11.3) years and 62.4% of the cohort were women. We found significant improvements post-EECP treatment in CCS angina class (mean (SD) 3.4 (0.5) to 2.4 (2.9), p <0.001), 6-minute walk test (median 1200 (IQR 972 to 1411) to 1358 (1170 to 1600), p <0.001), DASI (mean (SD) 15.2 (11.6) to 31.5 (16.3), p <0.001), SAQ7 (mean (DS) 36.2 (24.7) to 31.5 (16.3), p <0.001), and weekly anginal episodes (mean (SD) 5.3 (3.5) to 2.4 (2.9), p <0.001). After EECP treatment, 71 patients (70.3%) had an improvement of ≥1 CCS angina class, including 33 (32.7%) patients improving by ≥2 CCS classes. In conclusion, in patients with ANOCA, EECP therapy reduces CCS angina class and improves exercise tolerance and capacity; and should be considered a part of optimal medical therapy.
心绞痛和非阻塞性冠状动脉疾病(ANOCA)与不良预后及有限的治疗选择相关。增强型体外反搏(EECP)是一种非侵入性治疗方法,通过在下肢应用外部充气袖带,在舒张期增加血流,在收缩期放气。尽管EECP已被批准用于治疗因阻塞性冠状动脉疾病导致的难治性心绞痛患者,但其在治疗伴有难治性心绞痛的ANOCA患者中的有效性仅限于小型研究。我们通过测量加拿大心血管学会(CCS)心绞痛分级、6分钟步行试验、杜克活动状态指数(DASI)、西雅图心绞痛问卷7项(SAQ7)以及EECP治疗前和治疗后每周心绞痛发作次数的变化,评估了EECP治疗对ANOCA(定义为任何主要心外膜血管狭窄≤50%)伴难治性心绞痛患者的疗效。共有101例CCS III/IV级心绞痛的ANOCA患者在2个大型EECP中心完成了一个完整疗程的EECP治疗。101例ANOCA患者的平均年龄(标准差)为60.6(11.3)岁,队列中62.4%为女性。我们发现EECP治疗后,CCS心绞痛分级(平均(标准差)从3.4(0.5)降至2.4(2.9),p<0.001)、6分钟步行试验(中位数从1200(四分位间距972至1411)增至1358(1170至1600),p<0.001)、DASI(平均(标准差)从15.2(11.6)增至31.5(16.3),p<